Cargando…

Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease

Chronic respiratory diseases are the third leading cause of death, behind cardiovascular diseases and cancer, affecting approximately 550 million of people all over the world. Most of the chronic respiratory diseases are attributable to asthma and chronic obstructive pulmonary disease (COPD) with th...

Descripción completa

Detalles Bibliográficos
Autores principales: Facchinetti, Fabrizio, Civelli, Maurizio, Singh, Dave, Papi, Alberto, Emirova, Aida, Govoni, Mirco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650159/
https://www.ncbi.nlm.nih.gov/pubmed/34887752
http://dx.doi.org/10.3389/fphar.2021.740803
_version_ 1784611147771543552
author Facchinetti, Fabrizio
Civelli, Maurizio
Singh, Dave
Papi, Alberto
Emirova, Aida
Govoni, Mirco
author_facet Facchinetti, Fabrizio
Civelli, Maurizio
Singh, Dave
Papi, Alberto
Emirova, Aida
Govoni, Mirco
author_sort Facchinetti, Fabrizio
collection PubMed
description Chronic respiratory diseases are the third leading cause of death, behind cardiovascular diseases and cancer, affecting approximately 550 million of people all over the world. Most of the chronic respiratory diseases are attributable to asthma and chronic obstructive pulmonary disease (COPD) with this latter being the major cause of deaths. Despite differences in etiology and symptoms, a common feature of asthma and COPD is an underlying degree of airways inflammation. The nature and severity of this inflammation might differ between and within different respiratory conditions and pharmacological anti-inflammatory treatments are unlikely to be effective in all patients. A precision medicine approach is needed to selectively target patients to increase the chance of therapeutic success. Inhibitors of the phosphodiesterase 4 (PDE4) enzyme like the oral PDE4 inhibitor roflumilast have shown a potential to reduce inflammatory-mediated processes and the frequency of exacerbations in certain groups of COPD patients with a chronic bronchitis phenotype. However, roflumilast use is dampened by class related side effects as nausea, diarrhea, weight loss and abdominal pain, resulting in both substantial treatment discontinuation in clinical practice and withdrawal from clinical trials. This has prompted the search for PDE4 inhibitors to be given by inhalation to reduce the systemic exposure (and thus optimize the systemic safety) and maximize the therapeutic effect in the lung. Tanimilast (international non-proprietary name of CHF6001) is a novel highly potent and selective inhaled PDE4 inhibitor with proven anti-inflammatory properties in various inflammatory cells, including leukocytes derived from asthma and COPD patients, as well as in experimental rodent models of pulmonary inflammation. Inhaled tanimilast has reached phase III clinical development by showing promising pharmacodynamic results associated with a good tolerability and safety profile, with no evidence of PDE4 inhibitors class-related side effects. In this review we will discuss the main outcomes of preclinical and clinical studies conducted during tanimilast development, with particular emphasis on the characterization of the pharmacodynamic profile that led to the identification of target populations with increased therapeutic potential in inflammatory respiratory diseases.
format Online
Article
Text
id pubmed-8650159
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86501592021-12-08 Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease Facchinetti, Fabrizio Civelli, Maurizio Singh, Dave Papi, Alberto Emirova, Aida Govoni, Mirco Front Pharmacol Pharmacology Chronic respiratory diseases are the third leading cause of death, behind cardiovascular diseases and cancer, affecting approximately 550 million of people all over the world. Most of the chronic respiratory diseases are attributable to asthma and chronic obstructive pulmonary disease (COPD) with this latter being the major cause of deaths. Despite differences in etiology and symptoms, a common feature of asthma and COPD is an underlying degree of airways inflammation. The nature and severity of this inflammation might differ between and within different respiratory conditions and pharmacological anti-inflammatory treatments are unlikely to be effective in all patients. A precision medicine approach is needed to selectively target patients to increase the chance of therapeutic success. Inhibitors of the phosphodiesterase 4 (PDE4) enzyme like the oral PDE4 inhibitor roflumilast have shown a potential to reduce inflammatory-mediated processes and the frequency of exacerbations in certain groups of COPD patients with a chronic bronchitis phenotype. However, roflumilast use is dampened by class related side effects as nausea, diarrhea, weight loss and abdominal pain, resulting in both substantial treatment discontinuation in clinical practice and withdrawal from clinical trials. This has prompted the search for PDE4 inhibitors to be given by inhalation to reduce the systemic exposure (and thus optimize the systemic safety) and maximize the therapeutic effect in the lung. Tanimilast (international non-proprietary name of CHF6001) is a novel highly potent and selective inhaled PDE4 inhibitor with proven anti-inflammatory properties in various inflammatory cells, including leukocytes derived from asthma and COPD patients, as well as in experimental rodent models of pulmonary inflammation. Inhaled tanimilast has reached phase III clinical development by showing promising pharmacodynamic results associated with a good tolerability and safety profile, with no evidence of PDE4 inhibitors class-related side effects. In this review we will discuss the main outcomes of preclinical and clinical studies conducted during tanimilast development, with particular emphasis on the characterization of the pharmacodynamic profile that led to the identification of target populations with increased therapeutic potential in inflammatory respiratory diseases. Frontiers Media S.A. 2021-11-23 /pmc/articles/PMC8650159/ /pubmed/34887752 http://dx.doi.org/10.3389/fphar.2021.740803 Text en Copyright © 2021 Facchinetti, Civelli, Singh, Papi, Emirova and Govoni. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Facchinetti, Fabrizio
Civelli, Maurizio
Singh, Dave
Papi, Alberto
Emirova, Aida
Govoni, Mirco
Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease
title Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease
title_full Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease
title_fullStr Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease
title_full_unstemmed Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease
title_short Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease
title_sort tanimilast, a novel inhaled pde4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8650159/
https://www.ncbi.nlm.nih.gov/pubmed/34887752
http://dx.doi.org/10.3389/fphar.2021.740803
work_keys_str_mv AT facchinettifabrizio tanimilastanovelinhaledpde4inhibitorforthetreatmentofasthmaandchronicobstructivepulmonarydisease
AT civellimaurizio tanimilastanovelinhaledpde4inhibitorforthetreatmentofasthmaandchronicobstructivepulmonarydisease
AT singhdave tanimilastanovelinhaledpde4inhibitorforthetreatmentofasthmaandchronicobstructivepulmonarydisease
AT papialberto tanimilastanovelinhaledpde4inhibitorforthetreatmentofasthmaandchronicobstructivepulmonarydisease
AT emirovaaida tanimilastanovelinhaledpde4inhibitorforthetreatmentofasthmaandchronicobstructivepulmonarydisease
AT govonimirco tanimilastanovelinhaledpde4inhibitorforthetreatmentofasthmaandchronicobstructivepulmonarydisease